UBS Group’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

UBS Group’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2K	Buy	20,008 +19,900	+18,426%	+$2.72K	﹤0.01%	10107
2026 Q2	$12	Buy	+108	New	+$11	﹤0.01%	10314
2025 Q4	–	Sell	-150	Closed	-$33	–	11478
2025 Q3	$33	Buy	+150	New	+$28	﹤0.01%	10068

Other funds holding DMAAR

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $990M AUM 4.73% 1-Year Est. Return

UBS Group's DMAAR Position: Q3 2026 in Review

UBS Group increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 18,426% in Q3 2026, buying an estimated $2.72K and bringing the position to 20,008 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #10107.

UBS Group first reported a position in DMAAR in Q3 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold DMAAR as of Q3 2026.

UBS Group held 20,008 shares of Drugs Made In America Acquisition Corp Rights worth $2K as of Q3 2026.
UBS Group bought 19,900 Drugs Made In America Acquisition Corp Rights shares in Q3 2026, an estimated $2.72K.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10107 holding.
UBS Group first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 3 quarters since.
5 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.